Portage Biotech (PRTG)
(Delayed Data from NSDQ)
$9.30 USD
-0.67 (-6.72%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $9.67 +0.37 (3.98%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PRTG 9.30 -0.67(-6.72%)
Will PRTG be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PRTG based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for PRTG
Portage Biotech Reports Improved Fiscal Year Results
Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025 | PRTG Stock News
Portage Biotech Inc. Enters ATM Agreement with Rodman & Renshaw
Why Worthington Steel Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
12 Health Care Stocks Moving In Wednesday's Pre-Market Session